Literature DB >> 14717808

Nondialytic management of hyperkalemia and pulmonary edema among end-stage renal disease patients: an evaluation of the evidence.

Kimberley Evans1, Donal N Reddan, Lynda Anne Szczech.   

Abstract

Congestive heart failure (CHF) and hyperkalemia are the two leading reasons for emergency dialysis among individuals with end-stage renal disease (ESRD). While hemodialysis provides definitive treatment of both hyperkalemia and volume overload among ESRD patients, for those who present outside of "regular dialysis hours," institution of dialysis may be delayed. Nondialytic management can be instituted immediately and should be the initial therapy in the management of hyperkalemia and CHF in these individuals. Current available evidence does not allow conclusions as to whether treatment with nondialytic strategies alone results in different outcomes than nondialytic strategies coupled with emergent hemodialysis. Therefore, whether or not nondialytic management alone is appropriate remains a matter of individual judgment that should be decided on a case-by-case basis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14717808     DOI: 10.1111/j.1525-139x.2004.17110.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  3 in total

Review 1.  [Dialysis patients in intensive care units].

Authors:  H P Kierdorf
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-03-17       Impact factor: 0.840

2.  Serum Potassium Levels at Hospital Discharge and One-Year Mortality among Hospitalized Patients.

Authors:  Charat Thongprayoon; Wisit Cheungpasitporn; Sorkko Thirunavukkarasu; Tananchai Petnak; Api Chewcharat; Tarun Bathini; Saraschandra Vallabhajosyula; Michael A Mao; Stephen B Erickson
Journal:  Medicina (Kaunas)       Date:  2020-05-14       Impact factor: 2.430

3.  Severe hyperkalemia requiring hospitalization: predictors of mortality.

Authors:  Jung Nam An; Jung Pyo Lee; Hee Jung Jeon; Do Hyoung Kim; Yun Kyu Oh; Yon Su Kim; Chun Soo Lim
Journal:  Crit Care       Date:  2012-11-21       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.